Skip to main content
IRMD logo

IRMD · Iradimed Corp · Financials

Track IRMD — free
$83.95 -0.68 (-0.80%) At close · Oct 27 Q2 2026 earnings call transcript
Market Cap
$1.08B
Shares
12.79M
Volume · Oct 27 127.15K Avg daily vol (3M) 123.45K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$83.81M +14.4%
FY2025 Revenue FY2013–FY2025
Net Income
$22.48M +16.9%
FY2025 Net Income FY2013–FY2025
Gross Margin
76.75% -0.2pp
FY2025 Gross Margin FY2013–FY2025
Operating Margin
31.2% +1.2pp
FY2025 Operating Margin FY2013–FY2025
Diluted EPS
$1.75 +16.7%
FY2025 Diluted EPS FY2013–FY2025
Operating Cash Flow
$24.95M -2.6%
FY2025 Operating Cash Flow FY2013–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2026 (G) TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013
$91M – $96M $86.34M $83.81MG $73.24M $65.56MG $53.3MG $41.81MG $31.72M $38.52M $30.44M $23.08M $32.5M $31.59M $15.65M $11.34M
— $20.84M $19.49M $16.89M $15.4M $12.02M $9.76M $8.14M $8.82M $7.21M $5.57M $6.15M $5.84M $3.4M $2.85M
— $65.5M $64.32M $56.35M $50.16M $41.28M $32.05M $23.57M $29.7M $23.23M $17.51M $26.34M $25.75M $12.25M $8.49M
— — 76.75% 76.94% 76.5% 77.45% 76.65% 74.33% 77.11% 76.31% 75.87% 81.06% 81.51% 78.25% 74.84%
— $3.09M $2.98M $2.83M $2.86M $2.28M $1.91M $1.9M $1.43M $1.52M $1.72M $1.35M $1.76M $1.07M $1.01M
— $17.53M $17.42M $15.62M $12.14M $12.68M $10.56M $10.16M $9.17M $7M $5.5M $5.28M $4.71M $3.3M $2.3M
— $17.33M $17.78M $15.94M $15.12M $10.7M $9.77M $12.27M $10.45M $8.71M $9M $8.8M $7.77M $4.82M $2.39M
— $508K $370K $232K $117.05K $101.12K $101.74K $92.95K $89.96K $89.33K $82.4K $18.02K $36.01K $38.5K $37.59K
— $1.63M $1.17M $818K $765.18K $670.67K $1.41M $1.34M $1.24M $1.11M $1.31M $955.81K $807.26K $149.06K $139.04K
— $37.95M $38.18M $34.39M $30.12M $25.65M $22.23M $24.33M $21.05M $17.22M $16.23M $15.42M $14.24M $9.18M $5.7M
— $27.56M $26.15M $21.97M $20.04M $15.63M $9.82M -$756.09K $8.65M $6M $1.29M $10.92M $11.51M $3.07M $2.79M
— — 31.2% 29.99% 30.56% 29.32% 23.48% -2.38% 22.45% 19.72% 5.57% 33.6% 36.44% 19.59% 24.58%
— $29.18M $27.31M $22.78M $20.8M $16.3M $11.22M $582.73K $9.89M $7.11M $2.59M $11.88M $12.32M $3.21M $2.93M
— — $2.01M $2.19M $1.86M $581.85K $34.81K $132.19K $388.8K $238.11K $122.58K $126.42K $148.91K $5701 —
— $2.19M $2.21M $2.31M $1.7M $553.1K $18.61K $139.21K $395.91K $193.54K $111.38K $32.68K $121.39K -$48.55K -$3458
— — — — — $8025 $18.59K $17.27K $10.76K -$29.31K -$6761 -$83.96K -$3575 — —
— $29.75M $28.36M $24.28M $21.74M $16.18M $9.84M -$616.88K $9.04M $6.2M $1.4M $10.95M $11.63M $3.02M $2.78M
— $6.69M $5.88M $5.04M $4.55M $3.35M $510.82K -$1.99M -$587.64K -$106.14K $896.62K $3.74M $4.1M $966.98K $846.88K
— $23.06M $22.48M $19.23M $17.19M $12.83M $9.33M $1.37M $9.63M $6.3M $499.76K $7.21M $7.53M $2.05M $1.94M
— — 26.82% 26.26% 26.22% 24.07% 22.3% 4.32% 25% 20.71% 2.17% 22.2% 23.83% 13.1% 17.08%
— — — — $17.19M $12.81M $9.31M $1.38M $9.7M $6.32M $487.7K $7.23M $7.5M $2.03M $1.93M
USD/shares — $1.82 $1.77 $1.52 $1.36 $1.02 $0.76 $0.11 $0.85 $0.59 $0.05 $0.67 $0.68 $0.23 $0.28
USD/shares $1.90 – $2.05 $1.79 $1.75G $1.50 $1.35G $1.02G $0.74G $0.11 $0.78 $0.52 $0.04 $0.60 $0.60 $0.20 $0.22
shares — — 12.72M 12.67M 12.6M 12.56M 12.35M 12.12M 11.28M 10.76M 10.64M 10.82M 11M 8.74M 7M
shares — — 12.85M 12.78M 12.72M 12.64M 12.59M 12.44M 12.28M 12.11M 11.72M 11.99M 12.56M 10.22M 8.62M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2025: $11.79M in buybacks, $54.5M in dividends.

Debt Profile

Completed filing coverage through Nov 4, 2022

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Operating lease liabilities 2025-03-31 USD 59,221 10-Q filed 2025-05-05
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current operating lease liabilities
USD 59,221
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
11.85×
Peer median 2.98×
EV/EBIT
37.13×
Peer median 22.49×
P/E (TTM)
47.28×
Peer median 27.39×

Peer medians compare against the 65 similar-size Medical Devices companies (of 156 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Geography (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
United States $70,558,000 $60,607,000 $52,525,449 $43,898,735 $33,462,659 $24,535,443 $30,930,267 $24,508,026
Non Us $13,256,000 $12,635,000 — — — — — —
International — — $13,036,847 $9,404,410 $8,351,922 $7,181,929 $7,586,874 $5,930,957
Key facts CIK 1325618 CUSIP 46266A109 13F (30d) 43 filings 38 filers Visit website Investor relations